Stem cell transplant for Waldenström macroglobulinemia: an underutilized technique
- 29 August 2011
- journal article
- review article
- Published by Springer Science and Business Media LLC in Bone Marrow Transplantation
- Vol. 47 (9), 1147-1153
- https://doi.org/10.1038/bmt.2011.175
Abstract
Waldenström macroglobulinemia is a highly chemosensitive lymphoplasmacytic lymphoma with response rates of 90% to first-line chemotherapy. The fraction of patients undergoing stem cell transplant for this disorder appears to be lower than that of patients with multiple myeloma. The indolent nature and favorable genetic profile should make Waldenström an ideal disorder for autologous stem cell transplant, with high response rates that are durable. We review the literature on autologous and allogeneic transplants for Waldenström macroglobulinemia and conclude that autologous transplant is effective and underutilized in the management of this disorder. Allogeneic transplant should be considered investigational and used only in the context of a clinical trial or when other chemotherapeutic options have been exhausted.Keywords
This publication has 54 references indexed in Scilit:
- Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) GuidelinesMayo Clinic Proceedings, 2010
- Comparative Outcomes Following CP-R, CVP-R, and CHOP-R in Waldenström's MacroglobulinemiaClinical Lymphoma Myeloma and Leukemia, 2009
- Lymphoplasmacytic lymphoma–Waldenstrom's macroglobulinemiaCritical Reviews in Oncology/Hematology, 2008
- Waldenström macroglobulinaemiaBritish Journal of Haematology, 2007
- 6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosisBritish Journal of Haematology, 2006
- Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemiaBritish Journal of Haematology, 2006
- CHOP plus Rituximab Therapy in Waldenström's MacroglobulinemiaClinical Lymphoma, 2005
- Multicenter Phase 2 Trial of Rituximab for Waldenström Macroglobulinemia (WM): An Eastern Cooperative Oncology Group Study (E3A98)Leukemia & Lymphoma, 2004
- Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: An update of a US intergroup trial (SW0G S9003)Seminars in Oncology, 2003
- Forty Years with the Gamma GlobulinsScandinavian Journal of Immunology, 1987